ADC Therapeutics SA (ADCT)
4.70
+0.29
(+6.58%)
USD |
NYSE |
May 01, 16:00
4.70
0.00 (0.00%)
After-Hours: 20:00
ADC Therapeutics Enterprise Value: 198.09M for April 30, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 30, 2024 | 198.09M |
| April 29, 2024 | 205.51M |
| April 26, 2024 | 192.31M |
| April 25, 2024 | 200.56M |
| April 24, 2024 | 228.62M |
| April 23, 2024 | 244.30M |
| April 22, 2024 | 220.37M |
| April 19, 2024 | 223.67M |
| April 18, 2024 | 226.97M |
| April 17, 2024 | 243.48M |
| April 16, 2024 | 200.56M |
| April 15, 2024 | 194.79M |
| April 12, 2024 | 196.44M |
| April 11, 2024 | 220.37M |
| April 10, 2024 | 222.85M |
| April 09, 2024 | 228.62M |
| April 08, 2024 | 254.21M |
| April 05, 2024 | 246.78M |
| April 04, 2024 | 222.85M |
| April 03, 2024 | 199.74M |
| April 02, 2024 | 189.83M |
| April 01, 2024 | 200.56M |
| March 28, 2024 | 204.69M |
| March 27, 2024 | 180.76M |
| March 26, 2024 | 193.14M |
| Date | Value |
|---|---|
| March 25, 2024 | 180.76M |
| March 22, 2024 | 208.82M |
| March 21, 2024 | 214.59M |
| March 20, 2024 | 224.50M |
| March 19, 2024 | 219.54M |
| March 18, 2024 | 198.09M |
| March 15, 2024 | 146.09M |
| March 14, 2024 | 142.79M |
| March 13, 2024 | 156.00M |
| March 12, 2024 | 201.39M |
| March 11, 2024 | 201.39M |
| March 08, 2024 | 205.51M |
| March 07, 2024 | 244.30M |
| March 06, 2024 | 246.78M |
| March 05, 2024 | 231.92M |
| March 04, 2024 | 216.24M |
| March 01, 2024 | 235.23M |
| February 29, 2024 | 232.74M |
| February 28, 2024 | 235.21M |
| February 27, 2024 | 247.59M |
| February 26, 2024 | 258.32M |
| February 23, 2024 | 220.36M |
| February 22, 2024 | 237.69M |
| February 21, 2024 | 221.18M |
| February 20, 2024 | 231.91M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-178.24M
Minimum
Sep 22 2023
3.297B
Maximum
Jul 02 2020
892.28M
Average
511.83M
Median
Aug 12 2022
Enterprise Value Benchmarks
| Roche Holding AG | 217.15B |
| AC Immune SA | 121.10M |
| CRISPR Therapeutics AG | 2.804B |
| Addex Therapeutics Ltd | 3.937M |
| NLS Pharmaceutics Ltd | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -85.70M |
| Revenue (Quarterly) | 16.79M |
| Total Expenses (Quarterly) | 53.78M |
| EPS Diluted (Quarterly) | -1.05 |
| Gross Profit Margin (Quarterly) | 98.49% |
| Profit Margin (Quarterly) | -510.4% |
| Earnings Yield | -62.77% |
| Normalized Earnings Yield | -62.75 |